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We read with interest the meta-analysis and indirect compari-
son of levetiracetam and brivaracetam recently presented by
Zhang et al. (Seizure 2016;39:28–33) [1].Wewould like to raise two
points in response. Firstly, some methodological elements
common to indirect comparisons have not been addressed in
the publishedwork. Secondly, the use of networkmeta-analyses of
clinical trials to produce valid evidence of the comparative efﬁcacy
and safety of antiepileptic drugs (AEDs) has previously been called
into question, which was not discussed by the authors. Both of
these points lead us to believe that, given the presented evidence,
this publication overstates its comparative conclusions and
treatment recommendations.
We have a number of methodological concerns:1.htt
105
creWhile the search strategy is presented in full in the Appendix,
the rationale for excluding a number of randomised controlled
trials from the evidence base is not described [2–4]. Each of
these excluded trials has the potential to alter the results of the
analysis.2. A formal assessment of how known trial design differences (e.g.
duration of titration and formulation) affect the validity of the
comparison is not presented.3. The heterogeneity between trial populations for a small
selection of patient baseline characteristics is acknowledged
through the assessment of I2 values but not controlled for in the
comparison, in contrast to the basic principles of indirect
comparisons [5]. In addition, the selected baseline character-
istics may not be the only potential confounders.4. The trials used in the analysiswere published between 2000 and
2015; recruitment spanned a substantially longer period of
time. It is well known that AED trial populations have changed
over this period of time [6], for instance with regards to region,
prior treatment attempts, and comorbidity proﬁle. This is
exempliﬁed by large differences in placebo response (between
7.4% and 39.3%). No heterogeneity assessment is presented for
these potentially confounding characteristics, which is needed
to determine the validity of the comparison.5. Furthermore, it has been shown that placebo-response differ-
ences cannot be fully accounted for by measured patient
baseline characteristics only. Even using advanced matching
techniques on patient-level data to control for confounding,
unmeasured confounding between the brivaracetam and
levetiracetam populations remained [7]. The presence ofp://dx.doi.org/10.1016/j.seizure.2016.07.007
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ativecommons.org/licenses/by-nc-nd/4.0/).unmeasured confounding further undermines the validity of
comparison between these trials.6. Some of the studies in the meta-analysis included doses that
were found to be non-therapeutic in the pivotal studies and
have not been approved for clinical use (brivaracetam 5, 20 and
25mg/day; levetiracetam 500mg/day). As such, a brivaracetam
dose of 5mg/day should not be compared to a levetiracetam
dose of 1000mg/day.7. Considering the presented conﬁdence intervals, only one of the
36 comparisons reaches signiﬁcance. Broad conclusions on
potential differences in efﬁcacy and safety for levetiracetam and
brivaracetam are therefore not supported by the totality of
evidence presented.
The concerns highlighted above are not unique to the current
work. The conduct of indirect comparisons between AEDs is
complicated greatly by the design and population differences
between the trials, which can lead to confounding and bias [8].
We would like to note that whereas most indirect comparisons
conducted to date have found minor or no signiﬁcant differences
between AEDs (as in Zhang et al.), clinicians make individualised
and informed treatment choices daily, and real-world experience
often highlights the differences between AEDs and the value of
choice (aswill also be the case for levetiracetam and brivaracetam).
Indeed, for this reason the utility of indirect comparisons for
clinical decision-making has been questioned in the literature [8–
10] and concerns have been raised that, in the era of personalised
medicine, undue reliance on statistical approaches “may inappro-
priately limit patients’ choices” [11].
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